Intestinal Graft
Intestinal Graft - Related Videos
07:37
Mouse Models for Graft Arteriosclerosis
0 Views •
Cited by 17 •
2013
We describe protocols for our mouse graft arteriosclerois (GA) models which involve interposition of a mouse vessel segment into a recipient of the same inbred strain. By backcrossing additional genetic changes into the vessel donor, the model can assess the effect of specific genes on GA.
10:58
A Protocol for Lentiviral Transduction and Downstream Analysis of Intestinal Organoids
0 Views •
Cited by 81 •
2015
In this video protocol we give a step by step explanation of lentiviral transduction in organoids of primary intestinal epithelium and of processing and downstream analysis of these cultures by quantitative RT-PCR, RNA-microarray and immunohistochemistry.
09:50
Induction of Intestinal Graft-versus-host Disease and Its Mini-endoscopic Assessment in Live Mice
0 Views •
Cited by 3 •
2019
Here, we present a protocol that describes allogeneic hematopoietic stem cell transplantation and allows repetitive mini-endoscopic evaluations of the distal colon in situ for the presence, characteristics, and severity of colonic inflammation within live mice suffering from intestinal graft-versus-host disease.
12:39
Implantation of Inferior Vena Cava Interposition Graft in Mouse Model
0 Views •
Cited by 24 •
2014
To improve our knowledge of cellular and molecular neotissue formation, a murine model of the TEVG was recently developed. The grafts were implanted as infrarenal vena cava interposition grafts in C57BL/6 mice. This model achieves similar results to those achieved in our clinical investigation, but over a far shortened time-course.
08:25
A Rat Graft Rejection Model of Intestinal Transplantation with Exteriorized Ileostomy for Longitudinal Prognosis Assessment
0 Views •
2025
This protocol describes a rat-based intestinal transplantation model with ileostomy for time-course assessment of drug intervention on graft rejection.
FAQs
The recipient’s immune system may identify donor antigens as foreign, creating a risk of rejection. Immunosuppressive therapy acts by limiting this immune recognition and reducing the likelihood that the graft will be damaged. This immune-management strategy is essential for preserving graft function while clinicians continue evaluating the patient’s response over time.
Successful transplantation requires surgeons to connect the graft’s blood vessels to the recipient’s circulation and join the intestinal tract to the recipient’s digestive system. These connections support tissue viability and allow the transplanted intestine to participate in digestion and absorption. Their function is therefore closely linked to whether nutritional support can improve after transplantation.
These complications can threaten the performance and long-term success of an intestinal graft. Rejection reflects an adverse immune response, while infection and graft dysfunction represent additional problems requiring clinical attention. Monitoring helps clinicians identify changing graft status and manage complications that could otherwise limit nutritional benefit, enteral feeding, or quality of life.
Immunosuppressive therapy reduces immune recognition of donor antigens and lowers the risk of rejection, making it a central part of intestinal transplantation. However, treatment does not eliminate the need for follow-up because patients remain at risk for infection and graft dysfunction. Long-term care therefore combines immune control with continued assessment of graft performance.
An intestinal graft may be considered when the patient’s own intestine cannot provide adequate nutrition. If transplantation succeeds, the graft can support enteral feeding, reduce dependence on parenteral nutrition, and improve quality of life. Its clinical value is therefore measured not only by graft survival, but also by restoration of nutritional support and daily function.
Current research focuses on improving donor selection, refining immune management, and extending long-term graft survival. These priorities address different stages of transplantation: choosing a suitable graft, controlling the recipient’s response to donor tissue, and preserving function over time. Progress in all three areas could improve durability and the broader benefits of intestinal transplantation.